Role of PD-1/PD-L1 signaling axis in oncogenesis and its targeting by bioactive natural compounds for cancer immunotherapy
Yogesh Godiyal, Drishti Maheshwari, Hiroaki Taniguchi, Shweta S. Zinzuwadia, Yanelys Morera-Díaz, Devesh Tewari, Anupam Bishayee · 2024
Read Role of PD-1/PD-L1 signaling axis in oncogenesis and its targeting by bioactive natural compounds for cancer immunotherapy by Yogesh Godiyal, Drishti Maheshwari, Hiroaki Taniguchi, Shweta S. Zinzuwadia, Yanelys Morera-Díaz, Devesh Tewari, Anupam Bishayee (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11654217.txt.
Description
Yogesh Godiyal and six co-authors review a key immune brake in cancer and the natural compounds that may release it. Tumors use a protein pair, PD-1 and PD-L1, to quiet the immune cells that would attack them. Lab-made antibodies that block this pair have changed cancer care, though they can stir immune side effects in many organs. The review asks whether compounds from nature can act on the same brake.
Several natural agents have been shown to affect this path, slowing tumor growth and driving cancer cell death in studies. The authors map what is known and where the gaps remain for this added line of attack.
Catalog record
| CREATOR | Yogesh Godiyal, Drishti Maheshwari, Hiroaki Taniguchi, Shweta S. Zinzuwadia, Yanelys Morera-Díaz, Devesh Tewari, Anupam Bishayee |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 192 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |